We’re dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully.
Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. They’ve also driven shareholder value and built Jazz Pharmaceuticals into an employer of choice.
Bruce C. Cozadd brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team dedicated to patient-centered work.
Mr. Cozadd co-founded Jazz Pharmaceuticals in 2003 and has served as the Company’s Chairperson since founding and chief executive officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, including executive vice president and chief operating officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of chief financial officer and vice president of corporate planning and analysis. Mr. Cozadd is a member of the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on the Health Section Governing Board. Mr. Cozadd also serves as Chair of ACELYRIN, INC., a publicly-held biopharma company, and on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics & biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.
George Eliades, Ph.D., was appointed senior vice president of corporate development and chief transformation officer in December 2020. Dr. Eliades brings to Jazz significant global management consulting expertise from his 20 years of experience, 15 of which were in Bain & Company’s, San Francisco and Zurich offices. During his tenure at Bain, he primarily provided corporate strategy to clients in the biotech and pharmaceutical industries. Dr. Eliades has extensive experience supporting companies in oncology, neurology, endocrinology, ophthalmology and other specialty products. He brings deep experience in product launch and growth strategy driven by diagnostics and data.
From November 2007 to December 2020, Dr. Eliades was a partner at Bain & Company, where he focused primarily on advising biopharmaceutical clients. Dr. Eliades has advised numerous clients on their transformation agendas, including strategy, cost, M&A and digital driven transformation. Before joining Bain, Dr. Eliades was a consultant at Monitor Group serving global biopharmaceutical clients. Dr. Eliades serves on the board of directors for the Pulmonary Fibrosis Foundation and is a member of the board and the compensation committee for Oyster Point Pharma. Dr. Eliades has also advised nonprofits in the healthcare space, including the California Life Sciences Association and the American Society of Retina Specialists. Dr. Eliades received a B.A. from Harvard College, where he graduated magna cum laude with highest honors, and an M.A. and a Ph.D. from Harvard University.
Ms. Galá brings more than 25 years of experience across finance, strategy, leadership development and corporate development. Her role as CFO gives her oversight of all Jazz’s finance operations, including strategy, planning & analysis, investor relations, corporate development, and transformation functions. Ms. Galá’s prior experience as CFO of both another public company and a private company makes her especially skilled at the role. Ms. Galá became Jazz’s CFO in March 2020, and she is a passionate proponent of improving diversity within the healthcare industry.
Prior to joining Jazz, Ms. Galá served as the chief financial officer of GRAIL, Inc., a private healthcare company recently acquired by Illumina and focused on the early detection of cancer. Prior to that, from 2014 to 2019, she served as senior vice president and chief financial officer of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Innoviva, Inc. Ms. Galá joined Innoviva in 2006 and held various roles in the finance organization before leading the company’s spin-out transaction. Prior to that, Ms. Galá served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company from 2001 to 2006. Before joining Eli Lilly, Ms. Galá spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá serves on the board of directors and chairs the audit committees of Gossamer Bio, Inc., a clinical-stage biopharmaceutical company. Prior board member experience includes Gyroscope Therapeutics (acquired by Novartis) and Corcept Therapeutics. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
Robert Iannone has been Jazz’s executive vice president and global head of research and development since May 2019. Dr. Iannone oversees all aspects of preclinical research and clinical development, clinical operations and regulatory affairs. Dr. Iannone brings more than 16 years of experience in clinical drug development, having worked across therapeutic areas and phases of development, most recently on immuno-oncology programs at Merck, AstraZeneca and Immunomedics.
Fr From April 2018 until May 2019, Dr. Iannone served as head of research and development and chief medical officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of senior vice president and head of immuno-oncology, global medicines development and the global products vice president at AstraZeneca plc, a global science-led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as executive director and section head of oncology clinical development. From 2001 to 2004, he served as assistant professor of pediatrics and from 2004 to 2012 as adjunct assistant professor of pediatrics at the University of Pennsylvania School of Medicine. In 2021, Dr. Iannone was appointed to the board of directors for iTeos Therapeutics, a clinical-stage immune-oncology since May of 2021. Dr. Iannone has also served on the Cancer Steering Committee of the Biomarkers Consortium/Foundation for the National Institutes of Health since 2011. Dr. Iannone previously served on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company from January 2020 to May 2023. Dr. Iannone received a B.S. from The Catholic University of America with Summa Cum Laude honors, an M.D. from Yale University with Alpha Omega Alpha distinction and an M.S.C.E. from University of Pennsylvania. He completed his residency and chief residency in pediatrics and a fellowship in pediatric hematology-oncology at Johns Hopkins University.
Finbar Larkin, Ph.D., was appointed senior vice president of technical operations in October 2019. He has been with Jazz since 2013 and has made significant contributions to the Company’s evolution and transformation to an innovative biopharma company. He built the pharmaceutical development and manufacturing science organization responsible for chemistry manufacturing and controls (CMC) activities related to development, approval and launch of Sunosi, Xywav, Defitelio and Vyxeos. Dr. Larkin has responsibility for global pharmaceutical CMC development; manufacturing; supply chain; and new product and technology integration.
Dr. Larkin was appointed senior vice president of technical operations in October 2019. Dr. Larkin previously served as Jazz’s senior vice president of pharmaceutical development and manufacturing science from September 2018 until October 2019, vice president of technical development from February 2014 until August 2018, and executive director of technical operations from April 2013 until February 2014. Prior to that, from September 2009 until March 2013, Dr. Larkin served in management roles at Ipsen Pharma SAS, culminating in his role as vice president of engineering and senior specialist. From February 1997 until August 2009, he served as vice president and managing director at Ipsen Manufacturing Ireland. From 1990 until 1997, he served in various project and operational management roles at Novartis. Prior to 1990, Dr. Larkin served in various roles in manufacturing science and technology, human resources and quality and analytical science at Lilly SA. Dr. Larkin received a B.Sc. and Ph.D. in chemistry from University College Dublin.
Heidi Manna has been Jazz’s chief human resources officer since 2018 and oversees the human resources and internal communication functions for the Company. With more than 25 years of experience in human capital management across multiple industries including pharmaceuticals, consumer products, food and beverage and management consulting, she has developed expertise in HR strategy, talent management, culture development, organizational effectiveness, and change management. Ms. Manna is a purpose-driven strategist passionate about helping companies develop human capital and organizational development strategies to unlock the potential of people.
Prior to joining Jazz, from 2010 until 2018, she served as vice president of human resources at Campbell Soup Company, a global food company. While there, Ms. Manna held a variety of senior leadership positions in human resources across talent management, organizational development, workforce planning, and culture development to shape the human capital strategies for the business. She also led the transformation of the HR operating model to better serve the business. From 1996 to 2010, Ms. Manna held various leadership roles at Bristol-Myers Squibb, a global biopharmaceutical company, across a wide spectrum of the human resource function, including HR business partnership, talent management, operations and compensation. She started her career at Andersen Consulting (Accenture). Ms. Manna currently serves on the Employer Advisory Board for the University of Pennsylvania, and previously served on the board of directors for Seven Oaks Acquisition Corp, a special purpose acquisition company. She received a B.S. from Binghamton University and an M.B.A. from the State University of New York at Buffalo.
John Miller was appointed to senior vice president, corporate strategy in October, 2022. He was previously senior vice president of global product strategy and program management, after serving as vice president of global product strategy. Prior to that, Mr. Miller held various management roles within the oncology therapeutic area. He is currently responsible for leading corporate strategy and portfolio management, defining therapeutic and disease areas of interest to guide corporate development and R&D strategies and driving long-range planning.
John Miller was appointed senior vice president of global product strategy and program management as of September 2019. From February 2015 to September 2019, he served as Jazz’s vice president of global product strategy, and from August 2012 to February 2015, he served in various management roles within the oncology therapeutic area. Prior to that, from February 2012 to August 2012, Mr. Miller was director of US and global marketing, metabolic diseases at Alexion Pharmaceuticals, and from February 2011 to February 2012, he was director of strategic marketing at Enobia Pharma. Prior to February 2011, Mr. Miller served in various product commercialization roles at Jazz Pharmaceuticals, Inc., and Genzyme Corporation. Mr. Miller received a B.S. in biochemistry from the University of Mississippi and an M.B.A. from Boston University Graduate School of Management.
Neena M. Patil has served as Jazz’s chief legal officer since July 2019. Ms. Patil has been practicing law for 20 years and oversees all legal, corporate affairs and government relations matters for the Company. Ms. Patil is recognized for her track record of execution, including in connection with more than a dozen commercial launches and for her successful resolution of complex litigation, compliance investigations, and other corporate reputation matters. Ms. Patil has worked for several global biopharmaceutical companies over her career and currently serves on the board of Teleflex Inc., where she is a member of the Nominating and Corporate Governance Committee. She also serves on the board of mothers2mothers, a global women’s health organization operating in sub-Saharan Africa.
From September 2018 to July 2019, Ms. Patil served as senior vice president, general counsel and corporate secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as vice president for legal affairs and associate general counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Ms. Patil received a B.A. from Georgetown University and a J.D. and Master of Health Services Administration from the University of Michigan.
Samantha Pearce was appointed Jazz’s senior vice president of Europe and International in March 2020. With more than 30 years of experience in the pharmaceutical industry, Ms. Pearce has a track record of scaling commercial operations to achieve transformational growth and accelerated access to medicines across geographies. She is particularly passionate and effective at unifying teams around a singular vision and instilling a performance and enterprise mindset.
From March 2010 to December 2019, Ms. Pearce held various global senior management positions with Celgene Corporation, most recently as vice president and general manager of international markets. Prior to that, from August 2002 to March 2010, she served in management positions at AstraZeneca plc, culminating in her role as director of specialist care. Prior to August 2002, she worked for DuPont Pharmaceuticals. Ms. Pearce received a B.Sc. from Birmingham University, U.K. and an M.B.A. from Cranfield University, UK.
Kim Sablich oversees all of Jazz’s US regional business structure, which includes Jazz’s medical affairs, commercial and market access teams. Ms. Sablich has deftly developed and managed a strategically-aligned and integrated customer-facing organization since she joined Jazz in June 2020.
Ms. Sablich previously served as chief commercial officer of Myovant Sciences, Inc., a clinical-stage biopharmaceutical company, from December 2018 to May 2020. Prior to that, she served in various executive roles at GlaxoSmithKline plc, a multinational pharmaceutical company, including as vice president of U.S. primary care marketing from May 2015 to May 2018, as vice president of global medicines commercialization from July 2013 to May 2015, and as vice president of U.S. vaccines commercial strategy from October 2010 to June 2013. Prior to 2010, Ms. Sablich served in various positions of increasing responsibility at Merck & Company, a global healthcare company, in its commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory, and vaccines business areas. She serves on the board of directors of Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on rare diseases. Ms. Sablich holds a B.A. in economics from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.
Daniel N. Swisher, Jr. was appointed Jazz’s president in January 2018. Mr. Swisher has extensive experience in the advancement and commercialization of novel therapeutics across multiple therapeutic areas including neuroscience, metabolic, and targeted cancer agents. As president and chief operating officer, he oversees the commercial and operating businesses, as well as research and development and global product commercialization and commercial development. Throughout his career, Mr. Swisher has exhibited and encouraged global operational excellence to foster innovation.
From December 2003 to December 2017, Mr. Swisher was chief executive officer and a member of the board of directors of Sunesis Pharmaceuticals, a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as chief business officer and chief financial officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including senior vice president of sales and marketing for ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
